Member Info for BlahBlahDoh

The interim has already been paid Banana - 6p last September. The progressive dividend policy suggests a figure around 12p for the upcoming final, giving a total of about 18p. That would give the spectacular yield you mention.

That's why I suspect that maintaining the dividend could attract attention: M&G has the best yield on the FTSE100, yet many casual investors may be unaware of that fact. M&G have still not had a full years results as an individual company, and therefore the real yield has been obscured - a situation which ends next month.

It's always possible M&G could review their dividend policy based on trading conditions, but it seems unlikely.

The interim dividend you refer to as "quite possible" is for the next financial year, payable in September (6p again, I'd guess).

Hoping, if Nano wins they should insist on a free TV, phone and watch for all shareholders as part of the settlement - it's only fair (-;

Hawi's document link echoes many of the points made elsewhere, how the East Texas court is somewhat notorious as a fast and easy place for frivolous patent litigation targeted by frequent complainants seeking minor settlements. My strong impression is that Nanoco is not one of those cases, in fact all of the cases against Samsung that I am aware of seem to be genuine issues, cases brought reluctantly as a last resort. Noticeably they don't take licenses where other companies do, that has happened more than once, so they are simply not playing on a level playing field compared to their rivals. I wonder whether the courts alone can deal with this, it seems to me like a possible government-level trade issue.

"Samsung does not permit others to use its patent rights without paying for them, and it is safe to assume Samsung would not permit consumers to take its phones and watches without paying for them, so it defies logic that Samsung thinks it acceptable to misappropriate the patent rights of others. LG Display Co. recently licensed Solas’ patent portfolio"

Ouch! Solas really hammering the nail in there, and quite right too: Samsung are just out of control and need a wake up call.

Nicely put feeks: the missing "N" speaks volumes (or perhaps it's just very small?)

Final results due in about three weeks now: if they maintain the dividend, it should attract a lot of attention, imo

"they don't appear to have any ethics as "my word is my bond" isn't a phrase that they are obviously aware of"
If they have done their sums wrong and taken on risk they cannot cover, they may well be in trouble with regulators anyway, so it might be worth getting out in case there is a risk of bankruptcy or similar sudden closure: pure speculation based on their behaviour, but maybe worth considering?

"good to see you again Blah, so sad you didn't get your 23p entry you called last week"

Haha, quite funny a newbie making up stories. What prompted that weird accusation? I've been here since July 2019, Vivaldi, more than four seasons, and the only time I spoke about a good entry point was in late November 2020 with the dip after the Pfizer approval - you could have got in at around 23p then, and hopefully some did.

Not a gambler, but I thought all bookmakers did that. On the bright side, at least you found something else to moan about. Meanwhile, best week for ORPH since the hVivo deal, imo.

Don't know if it has anything to do with the SP recovery, but it's interesting that Jackson have been quietly filling most of the top positions with females of the species: notoriously more deadly than the male.

Like virtually everything written about wearables, it concentrates on measuring and monitoring vital signs. The value of ORPH's clinical data lies in the assumed presence of specific universal biomarkers which can be used to interpret those signs. By packaging the data as "platforms", ORPH are presumably presenting it in formats convenient for biomarker hunters, and their software. There is a lot of interest at a high level now, and discussions with commercial groups must be intensifying as the HC trials start test-driving vaccines at warp speed.

Didn't you miss out a stage dust? First we'd have to transfer from AIM to the main market, which in itself would attract new investors. I don't think CF has mentioned that yet, but its something to consider going forward.

Just five months ago, before the govt. contract, we were trading around 13p. This approval confirms the news which caused the rerate to around 25p. Anyone invested here can see how this decision, at a stroke, unlocks all sorts of doors for future contracts and newsflow, but it will take some time for people less savvy, good looking and fabulous than ourselves, to catch up. Another rerate, maybe two, are certainly possible if the story pans out as we hope, and no chance of a "bargain takeover" with CF in charge: he'll make them pay top renmimbi.

Apologies if this has already been posted. Yet another example of the depth of corruption and illegal activity at Samsung over a long period. It's getting to the point where they should be regarded as guilty until proven innocent.

"More than 30 Samsung executives and officials were indicted in 2018 on charges of leading and engaging in groupwide efforts to neutralize the labor union at Samsung Electronics Service, a customer service affiliate, by gathering personal information about members and leaking sensitive personal data to force them to leave the union."

http://www.koreaherald.com/view.php?ud=20210204000483

Trading statement at last! Terrific to see the potential confirmed, with significant revenue and cash generation kicking in for the first time. Excellent performance given the conditions: solid commercial progress.

"The approval is a pivot point. I've been very relaxed that this was coming - but it was great to read that RNS this morning :-)"

Pivot point is absolutely right, FatherTedCrilly - if this had failed the ethics test then a lot of potential future business would have been closed off, but that is all now free and clear, and actually something to be moderately excited about. In reality the approval only took a few weeks longer than expected. That delay is significant in terms of lives lost, but it reflects the seriousness of the decision. SP rise seems modest so far, but we're already up significantly this calendar year, and probably more to come when the market fully realises the somewhat complicated, but highly positive, implications for ORPH.

My point was that it is from a US organisation TR3, therefore presumably aimed at US citizens, and it contains details for potential recruits to respond to, so it is a listing for recruitment purposes, and not any sort of proof of approval as you seem to imagine. The listing is careful to state "Listing a study does not mean it has been evaluated by the U.S. Federal Government." If it had passed any UK regulatory approval, then it would surely be mentioned here, but as I said, AFAIK there is no need for approval for recruitment. The failure of the Health Minister to mention any approvals when directly questioned about CHIM studies a few days ago also suggests that there have been none. Yet.

LTHs might see it as a positive, because retaining market share and brand loyalty is ultimately more important than the margin or SP, which can both be recovered faster and easier. Eventually! Admittedly, it was a defensive move, but surely appropriate during a pandemic. It may not be long before the numbers show this was a relatively short term measure with long term benefits, with unprecedented vaccine programmes and warmer weather hammering the virus right on it's spike.

That link appears to be for recruitment of US volunteers. There is no regulatory approval needed for that, AFAIK? It states that recruits will only be invited to participate after regulatory approval for the study is granted. It doesn't seem reasonable to ask others to provide proof of the absence of approval, we can assume it is absent until proved otherwise.

Indications in October from CF and the UK government gave the distinct impression that approval was imminent ahead of a January start. The obvious interpretation is that the arrival of 3 highly effective vaccines has swayed ethical doubts, and the subsequent arrival of multiple worrisome mutations has swayed them back, with the ethics people unwilling to commit either way? In other words, a moral maze, an ethical dilemma rather than a political one.

"the firm’s valuation rose thanks to the release of new products (QD materials)"
"its QD materials shipment growth should accelerate in 2H21 on higher usage of QD OLED products. Of note, the amount of the QD OLED materials needed to produce one OLED TV unit is 5x larger than that for existing QD materials."
"We forecast overall 1Q21 OP of W50.4bn (+43.4% y-y, +88.2% q-q) and full-year 2021 OP of 206.3bn (+35.8% y-y)"

This should be the year Nano took off, but instead a South Korean paper manufacturer has stolen our thunder, our IP, and our operating profits. After we give Samsung a haircut, we should go after them for handling stolen goods.

Nothing wrong with reposting with new people arriving all the time. Who can keep up with all the ramping, stamping and "subtle" deramping anyway? Good luck to all Fourty-niners with a stake in this gold rush